

Giorgio Valabrega

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/212515/publications.pdf>

Version: 2024-02-01

73
papers

2,015
citations

279778

23
h-index

265191

42
g-index

75
all docs

75
docs citations

75
times ranked

3480
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy. <i>Oncologist</i> , 2006, 11, 318-324. | 3.7 | 116 |
| 2 | Ovarian Cancer Immunotherapy: Turning up the Heat. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2927. | 4.1 | 116 |
| 3 | TGF β expression impairs Trastuzumab-induced HER2 downregulation. <i>Oncogene</i> , 2005, 24, 3002-3010. | 5.9 | 113 |
| 4 | PARP Inhibitors in Ovarian Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2018, 13, 392-410. | 1.6 | 102 |
| 5 | Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 257-268. | 3.1 | 96 |
| 6 | Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. <i>Oncotarget</i> , 2017, 8, 90532-90544. | 1.8 | 89 |
| 7 | Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. <i>World Journal of Clinical Oncology</i> , 2014, 5, 990. | 2.3 | 87 |
| 8 | Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4414. | 4.1 | 87 |
| 9 | Moderate Immunohistochemical Expression of HER-2 (2+) Without <i>HER-2</i> Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer. <i>Oncologist</i> , 2012, 17, 1418-1425. | 3.7 | 79 |
| 10 | Multitarget drugs: the present and the future of cancer therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 589-600. | 1.8 | 66 |
| 11 | Olaparib as maintenance therapy in patients with BRCA 1/2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome. <i>Gynecologic Oncology</i> , 2020, 156, 38-44. | 1.4 | 62 |
| 12 | Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients. <i>Cancer</i> , 2012, 118, 17-26. | 4.1 | 58 |
| 13 | Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications. <i>Cancers</i> , 2019, 11, 1820. | 3.7 | 57 |
| 14 | Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives. <i>Diagnostics</i> , 2020, 10, 146. | 2.6 | 56 |
| 15 | Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1169. | 4.1 | 53 |
| 16 | Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4203. | 4.1 | 49 |
| 17 | HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 29-40. | 2.5 | 47 |
| 18 | Trastuzumab-based combination therapy for breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 81-96. | 1.8 | 43 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. <i>Molecular Oncology</i> , 2014, 8, 20-26. | 4.6 | 37 |
| 20 | CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2839. | 4.1 | 34 |
| 21 | Adoptive immunotherapy against ovarian cancer. <i>Journal of Ovarian Research</i> , 2016, 9, 30. | 3.0 | 33 |
| 22 | Buparlisib, an oral pan-PI3K inhibitor for the treatment of breast cancer. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 421-431. | 4.1 | 29 |
| 23 | Immunotherapy in cervix cancer. <i>Cancer Treatment Reviews</i> , 2020, 90, 102088. | 7.7 | 28 |
| 24 | Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis. <i>Cancers</i> , 2020, 12, 2156. | 3.7 | 27 |
| 25 | Retrospective Evaluation of Clinical Outcomes in Patients with HER2-Positive Advanced Breast Cancer Progressing on Trastuzumab-Based Therapy in the Pre-Lapatinib Era. <i>Clinical Breast Cancer</i> , 2008, 8, 436-442. | 2.4 | 25 |
| 26 | Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2353. | 4.1 | 24 |
| 27 | A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two-centers experience. <i>Journal of Ovarian Research</i> , 2018, 11, 42. | 3.0 | 21 |
| 28 | Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2012, 19, 3755-3761. | 1.5 | 20 |
| 29 | TOP2A as marker of response to pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancers. <i>Journal of Ovarian Research</i> , 2019, 12, 17. | 3.0 | 20 |
| 30 | Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e92. | 2.2 | 20 |
| 31 | The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. <i>Gynecologic Oncology</i> , 2019, 153, 535-540. | 1.4 | 19 |
| 32 | Recent advances in the development of breast cancer vaccines. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 159. | 1.8 | 18 |
| 33 | Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. <i>Cancers</i> , 2020, 12, 1315. | 3.7 | 18 |
| 34 | Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 26181-26191. | 1.8 | 15 |
| 35 | Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3559. | 4.1 | 15 |
| 36 | Ovarian Cancer Cells in Ascites Form Aggregates That Display a Hybrid Epithelial-Mesenchymal Phenotype and Allows Survival and Proliferation of Metastasizing Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 833. | 4.1 | 14 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Trastuzumab-Related Cardiotoxicity in the Herceptin Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2008, 26, 2052-2053. | 1.6 | 13 |
| 38 | Androgen receptor status predicts development of brain metastases in ovarian cancers. <i>Oncotarget</i> , 2017, 8, 41143-41153. | 1.8 | 13 |
| 39 | Potential of afatinib in the treatment of patients with HER2-positive breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2012, 4, 131. | 1.8 | 12 |
| 40 | A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. <i>Breast Journal</i> , 2015, 21, 241-245. | 1.0 | 12 |
| 41 | Trastuzumab Treatment in Breast Cancer. <i>New England Journal of Medicine</i> , 2006, 354, 2186-2186. | 27.0 | 11 |
| 42 | Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 549-565. | 1.8 | 9 |
| 43 | New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2179-2189. | 1.8 | 9 |
| 44 | Veliparib: a new therapeutic option in ovarian cancer?. <i>Future Oncology</i> , 2019, 15, 1975-1987. | 2.4 | 9 |
| 45 | Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21). <i>Gynecologic Oncology</i> , 2021, 161, 755-761. | 1.4 | 9 |
| 46 | The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality. <i>Frontiers in Oncology</i> , 2021, 11, 689829. | 2.8 | 9 |
| 47 | Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. <i>BMC Cancer</i> , 2008, 8, 209. | 2.6 | 8 |
| 48 | Role of trastuzumab in the management of HER2-positive metastatic breast cancer. <i>Breast Cancer: Targets and Therapy</i> , 2010, 2, 93. | 1.8 | 8 |
| 49 | Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. <i>Oncologist</i> , 2010, 15, 665-672. | 3.7 | 8 |
| 50 | p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy. <i>Oncotarget</i> , 2016, 7, 4442-4453. | 1.8 | 8 |
| 51 | From Uterus to Brain: An Update on Epidemiology, Clinical Features, and Treatment of Brain Metastases From Gestational Trophoblastic Neoplasia. <i>Frontiers in Oncology</i> , 2022, 12, 859071. | 2.8 | 8 |
| 52 | PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. <i>Cells</i> , 2020, 9, 442. | 4.1 | 7 |
| 53 | Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 2143-2156. | 1.8 | 6 |
| 54 | Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience. <i>Cancers</i> , 2020, 12, 2239. | 3.7 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers. <i>Journal of Ovarian Research</i> , 2020, 13, 53. | 3.0 | 6 |
| 56 | SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5610-TPS5610. | 1.6 | 6 |
| 57 | Controversies in breast cancer: adjuvant and neoadjuvant therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1055-1072. | 1.8 | 5 |
| 58 | Trastuzumab Beyond Disease Progression: Case Closed?. <i>Journal of Clinical Oncology</i> , 2009, 27, e121-e122. | 1.6 | 5 |
| 59 | Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 359-367. | 3.1 | 5 |
| 60 | A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1205-1207. | 2.5 | 5 |
| 61 | Modeling ErbB2-p130Cas interaction to design new potential anticancer agents. <i>Scientific Reports</i> , 2019, 9, 3089. | 3.3 | 4 |
| 62 | Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: a retrospective MITO group study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, ijgc-2020-002343. | 2.5 | 4 |
| 63 | Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer. <i>Cells</i> , 2021, 10, 3408. | 4.1 | 4 |
| 64 | Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report. <i>In Vivo</i> , 2019, 33, 2021-2026. | 1.3 | 3 |
| 65 | Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1363-1368. | 2.5 | 3 |
| 66 | Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15095-e15095. | 1.6 | 3 |
| 67 | Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. <i>Oncologist</i> , 2011, 16, 534-536. | 3.7 | 1 |
| 68 | Is there a role for immunotherapy in ovarian cancer?. <i>Annals of Translational Medicine</i> , 2019, 7, S276-S276. | 1.7 | 1 |
| 69 | Translational Research in Ovarian Cancer. <i>Cancers</i> , 2020, 12, 3676. | 3.7 | 1 |
| 70 | Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5770. | 4.1 | 1 |
| 71 | Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 1179-1188. | 1.8 | 0 |
| 72 | Trastuzumab in the adjuvant setting: a practical review. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 161-177. | 0.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Are cyclin-dependent kinases 4/6 inhibitors ready for prime time in estrogen-receptor positive metastatic breast cancer?. <i>Translational Cancer Research</i> , 2017, 6, S197-S200. | 1.0 | 0 |